Hospital-acquired infections are type of infections acquired during hospitalization and are commonly known as nosocomial infection. These infections can be acquired in hospital, nursing home, rehabilitation facility, outpatient clinic, or other clinical settings. They can be acquired from an infected patient, outside environment, or from a staff of that facility. The hospital-acquired infection diagnostics market is primarily driven by the growth in awareness among healthcare workers and proposed government initiatives by many governmental organizations. Further, in developing economies such as China, India, and Brazil, the cleanliness and hygiene is minimum. Hence, it results in more hospital-acquired infections, which further increases the demand for hospital-acquired infection diagnostics. However, the decline in hospital-acquired infections in the developed countries such as the U.S., Germany, and the UK impedes the market growth. The hospital-acquired infection diagnostics market was valued at $2,571 million in 2016, and is expected to reach at $4,311 million by 2023, registering a CAGR of 7.5% from 2017 to 2023.
The hospital-acquired infection diagnostics market is segmented based on product, test type, application, infection type, end user and region. Based on product this market is segmented into instrument and reagents and consumables. Based on test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. Based on application, the market is divided into disease testing and drug resistance testing. Further, based on infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal Infections, urinary tract infections (UTI), and others. Based on end user this market is segmented into hospital, clinics, ambulatory surgery centres (ASC) and others. By region, the market is analysed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global hospital-acquired infections market, with current trends and future estimations to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps understand the type of products and technologies used globally.
Key market players and their strategies are provided to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product
Instrument and Reagents
Consumables
By Test Type
Molecular Diagnostics
Urinalysis
Immunoassay
By Application
Disease Testing and
Drug-Resistance Testing
By Infection Type
Hospital Acquired Pneumonia
Bloodstream Infections
Surgical Site Infections
Gastrointestinal Infections
Urinary Tract Infections (UTI)
Others
End User
Hospital
Clinics
Ambulatory Surgery Centers (ASC)
Others
BY REGION
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Argentina
Turkey
South Africa
Rest of LAMEA
KEY PLAYERS PROFILED
Abbott Laboratories
AdvanDX
Alere Inc.
AstraZeneca plc
Bayer Schering Pharma LLC
Becton Dickinson & Company
Cepheid Inc.
Roche AG
Daiichi Sankyo
Hologic, Inc.
The other players in the value chain include (profiles not included in the report)
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Meridien
Pfizer
Seegene
